|
Market Closed -
Nasdaq
16:00:00 2026-10-27 EDT
|
5-day change | 1st Jan Change | ||
| 15.33 USD | +5.72% |
|
-1.54% | -12.35% |
Company Valuation: Summit Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 1,436 | 10,512 | 10,021 | 8,686 | - | - |
| Change | - | 631.97% | -4.67% | -13.32% | - | - |
| Enterprise Value (EV) 1 | 1,436 | 10,512 | 9,493 | 8,424 | 8,684 | 8,390 |
| Change | - | 631.97% | -9.69% | -11.26% | 3.09% | -3.39% |
| P/E | -2.62x | -58.1x | -12.2x | -12.6x | -12.4x | -21.3x |
| PBR | - | - | 20.7x | 42.9x | 434x | 27.1x |
| PEG | - | 0.8x | -0x | 0.7x | -8.84x | 0.5x |
| Capitalization / Revenue | - | - | - | 2,958x | 207x | 20.3x |
| EV / Revenue | - | - | - | 2,869x | 207x | 19.6x |
| EV / EBITDA | - | -96.9x | -11.7x | -14.7x | -15.8x | -26.5x |
| EV / EBIT | - | -58.8x | -11.7x | -12.6x | -12x | -18.5x |
| EV / FCF | - | -93.4x | -39.6x | -14.8x | -12.3x | -14.6x |
| FCF Yield | - | -1.07% | -2.52% | -6.77% | -8.13% | -6.85% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -0.7828 | -0.2452 | -1.066 | -0.8609 | -0.873 | -0.5103 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | - | - | - | 2.936 | 41.93 | 428.8 |
| EBITDA 1 | - | -108.4 | -810.4 | -573.3 | -550.7 | -316.1 |
| EBIT 1 | - | -178.8 | -810.5 | -670.5 | -723.2 | -452.6 |
| Net income 1 | -486.2 | -175.1 | -799.5 | -696.6 | -738.3 | -431.8 |
| Net Debt 1 | - | - | -528.6 | -261.9 | -1.599 | -296.3 |
| Reference price 2 | 2.05 | 14.25 | 13.00 | 10.86 | 10.86 | 10.86 |
| Nbr of stocks (in thousands) | 700,843 | 737,448 | 771,150 | 799,726 | - | - |
| Announcement Date | 2/20/24 | 2/24/25 | 2/23/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -12.6x | 2869.18x | -14.69x | -.--% | 11.6B | |
| 18.07x | 6.54x | 12.9x | 1.78% | 65.28B | |
| 30.04x | 7.96x | 26.09x | 0.05% | 54.57B | |
| 36.97x | 6.56x | 19.6x | 0.88% | 53.59B | |
| 34.86x | 3.39x | 14.64x | -.--% | 45.03B | |
| 48.82x | 5.62x | 30.9x | -.--% | 42.17B | |
| -19.09x | 184.46x | -20.29x | -.--% | 39.42B | |
| 28.28x | 8.04x | 20.81x | 0.38% | 32.71B | |
| 27.72x | 5.84x | 15.15x | -.--% | 24.01B | |
| 36.39x | 6.61x | 22.07x | -.--% | 26.5B | |
| Average | 22.95x | 310.42x | 12.72x | 0.31% | 39.49B | |
| Weighted average by Cap. | 25.54x | 108.20x | 15.04x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- SMMT Stock
- Valuation Summit Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
